Mardepodect
Small moleculeexperimental
Clinical trial activity
11 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00463372)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 10AANTAGONIST
PDE10A antagonist
- Phosphodiesterase 10AINHIBITOR
Phosphodiesterase 10A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1- Mol. weight
- 392.46 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL562318 ↗
Also known as
- pf-02545920
- pf-02545920
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02342548 | Phase 2 | Feb 25, 2015 | Pfizer |
| NCT02197130 | Phase 2 | Sep 1, 2014 | Pfizer |
| NCT01918202 | Phase 1 | Mar 1, 2014 | Pfizer |
| NCT01939548 | Phase 2 | Oct 1, 2013 | Pfizer |
| NCT01806896 | Phase 2 | Sep 1, 2013 | Pfizer |
| NCT01829048 | Phase 1 | Mar 1, 2013 | Pfizer |
| NCT01244880 | Phase 1 | Apr 1, 2011 | Pfizer |
| NCT01175135 | Phase 2 | Oct 1, 2010 | Pfizer |
| NCT01103726 | Phase 1 | May 1, 2010 | Pfizer, Yale University |
| NCT00570063 | Phase 2 | Nov 1, 2007 | Pfizer |
| NCT00463372 | Phase 1 | Oct 1, 2006 | Pfizer |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 11 | 11 | 2 | 2006 |
| Yale University | Academic/Hospital | 1 | 0 | 1 | 2010 |
2 organizations
Page 1 / 1